2003•Clinical NephrologyRequires access

Tacrolimus in resistant primary membranous nephropathy - a report of 3 cases

Cheuk‐Chun Szeto, C. B. Leung, F M Lai, P K-T Li

Open publisher page 9 citations

Abstract

AIM: To study the efficacy and safety of tacrolimus in primary membranous nephropathy. METHOD: We describe 3 patients with primary membranous nephropathy who were either resistant to or could not tolerate steroid with or without cytotoxic agents. They were treated with tacrolimus 0.2 mg/kg/day for 6 months. The dosage of tacrolimus was adjusted to keep a whole blood tacrolimus level of 5-10 ng/ml. RESULTS: One patient had almost complete disappearance of proteinuria while the other 2 had at least 50% reduction in proteinuria. Proteinuria increased again in 2 of the patients after tacrolimus was stopped, but in neither of them proteinuria returned to the pretreatment level 6 months after tacrolimus was stopped. CONCLUSION: We conclude that tacrolimus may have a modest efficacy in the treatment of resistant membranous nephropathy.

About this research paper

What this paper is about

AIM: To study the efficacy and safety of tacrolimus in primary membranous nephropathy. METHOD: We describe 3 patients with primary membranous nephropathy who were either resistant to or could not tolerate steroid with or without cytotoxic agents. They were treated with tacrolimus 0.2 mg/kg/day for 6 months. The dosage of tacrolimus was adjusted to keep a whole blood tacrolimus level of 5-10 ng/ml. RESULTS: One patient had almost complete disappearance of proteinuria while the other 2 had at least 50% reduction in proteinuria. Proteinuria increased again in 2 of the patients after tacrolimus was stopped, but in neither of them proteinuria returned to the pretreatment level 6 months after tacrolimus was stopped. CONCLUSION: We conclude that tacrolimus may have a modest efficacy in the treatment of resistant membranous nephropathy.

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

AIM: To study the efficacy and safety of tacrolimus in primary membranous nephropathy. METHOD: We describe 3 patients with primary membranous nephropathy who were either resistant to or could not tolerate steroid with or without cytotoxic agents. They were treated with tacrolimus 0.2 mg/kg/day for 6 months. The dosage of tacrolimus was adjusted to keep a whole blood tacrolimus level of 5-10 ng/ml. RESULTS: One patient had almost complete disappearance of proteinuria while the other 2 had at least 50% reduction in proteinuria. Proteinuria increased again in 2 of the patients after tacrolimus was stopped, but in neither of them proteinuria returned to the pretreatment level 6 months after tacrolimus was stopped. CONCLUSION: We conclude that tacrolimus may have a modest efficacy in the treatment of resistant membranous nephropathy.

Key concepts: Tacrolimus, Medicine, Proteinuria, Membranous nephropathy, Urology, Gastroenterology, Internal medicine, Kidney

Related papers

Back to paper searchBrowse research topicsOriginal source
Tacrolimus in resistant primary membranous nephropathy - a report of 3 cases — Research Paper | ScholarLens